Role of recombinant human erythropoietin in predialysis patients of chronic renal failure
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1996; 6 (2): 111-113
em En
| IMEMR
| ID: emr-95955
Biblioteca responsável:
EMRO
ABSTRACT
Experience with erythropoietin in the treatment of anaemia in predialysis patients is limited. This study was designed to investigate the efficacy, safety and impact of recombinant Human Erythropoietin [r-HU EPO] in the treatment of anaemia in predialysis chronic renal failure patients. The study included 19 patients and the treatment was administration of 50 I.U /kg r-HU EPO subcutaneously twice a week. The dose was reduced to 25 I.U/kg when the Hb level reached between 10-11 gm /dl and stopped when it went above 11 gm/dl. No side effects occurred during the period of study. The study concluded that r-HU EPO therapy improves anaemia in predialysis patients and doses not accelerate the progress to end stage renal disease
Buscar no Google
Índice:
IMEMR
Assunto principal:
Eritropoetina
/
Diálise Renal
/
Anemia
/
Falência Renal Crônica
Idioma:
En
Revista:
J. Coll. Physicians Surg. Pak.
Ano de publicação:
1996